Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Marwa Fawzi
Cairo University, Egypt
Posters & Accepted Abstracts: Clin Exp Dermatol Res
Background: It still remains debatable whether peroxisome proliferator activated receptor gamma (PPAR�³) is pro or antineoplastic and its exact role in mycosis fungoides (MF) remains unclear. Objective: This prospective comparative study aimed to investigate the expression of PPAR�³ in MF and compare it with psoriatics and controls in a trial to deduce its possible role in MF. Also, we tried to clarify the relation between PPAR�³ and Bcl-2 in MF. Methods: Twenty MF patients, 20 psoriatic patients and 20 controls were included. All participants underwent a skin biopsy and immunohistochemical staining for both PPAR�³ and Bcl-2 were performed. Western blot analysis was performed for detection of both PPAR�³ and Bcl-2. Results: The mean area percent of PPAR�³ measured in the MF patients (57.1217�±9.502417) was significantly higher (P<0.001) when compared with that of both the psoriatics (2.989�±1.723) and controls (35.9357�±8.1789). The mean area percent of Bcl-2 in MF patients (9.3763�±6.6328) was significantly higher (P<0.001) than that of both the psoriatics (2.35�±1.35) and the controls (0.73105�±0.5302)]. Our results were confirmed using the western blot analysis. We detected a highly significant positive correlation between the PPAR�³ and Bcl-2 mean area percents in all patients. In our MF patients, both parameters were also positively correlated with the age of the patient, duration and stage of MF (P<0.05). Conclusion: Our data suggest a possible role for PPAR�³ in the pathogenesis of MF possibly through several mechanisms, one of which might be conferring upon the lymphoma cells, a survival advantage at least partially through up regulating Bcl-2.